Britain to study use of Lilly's weight loss drug to get people back to work
Study to gauge how obesity treatment impacts employment
Obesity costs health service 11 billion pounds a year
Health minister says impact of drug could be 'monumental'
Adds details in paragraphs 4 and 7, NHS comment paragraphs 11-12
By Alistair Smout
LONDON, Oct 15 (Reuters) -Britain will study whether the use of Eli Lilly's LLY.N weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.
Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation, after Lilly announced a 279 million pound ($365.4 million) investment in Britain as part of a flagship summit hosted by Prime Minister Keir Starmer.
The deal included "a major real-world study" on the effectiveness of tirzepatide, marketed as Mounjaro in Britain, which could reduce the burden on the state-run National Health Service.
Streeting said obesity was costing the NHS 11 billion pounds a year and meant people took more sick leave or were forced out of the jobs market altogether.
"The long-term benefits of these drugs could be monumental in our approach to tackling obesity," Streeting wrote in an article in the Telegraph newspaper.
"For many people, these weight-loss jabs will be life-changing, help them get back to work, and ease the demands on our NHS."
The University of Manchester will coordinate the study, which will have up to 3,000 participants, and collect data on "health-related quality of life and changes in participants' employment status and sick days from work."
Earlier this month, England's National Health Service outlined a plan to give the drug to nearly a quarter of a million people as part of a three-year plan.
Streeting said that while the drug would be a tool to tackle obesity, people would need to make lifestyle changes too so that the health service, already struggling after years of crises, was not put under further strain.
"The NHS can't be expected to always pick up the tab for unhealthy lifestyles," he said.
NHS Chief Executive Amanda Pritchard said the study would provide valuable insights for the health service.
"Obesity is one of the biggest public health issues we face, and we know weight loss drugs will be a game-changer," she said.
($1 = 0.7635 pounds)
Reporting by Alistair Smout
Editing by Christina Fincher
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
